{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-035865","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.916297+00:00","generated_at":"2026-06-19T16:40:04.197530+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M","bullets":["Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.","Acquires Amnis imaging and Guava flow cytometers; >60% of FCI employees are commercial, boosting Cytek's sales and service.","Acquisition aligns with DiaSorin's strategic priorities; Cytek expands global footprint and adds entry-level instrument options.","Cytek to host investor conference call Feb 13 at 4:30 PM ET; details at investors.cytekbio.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-035865","json":"https://secwatch.observer/filing/0001193125-23-035865.json","markdown":"https://secwatch.observer/filing/0001193125-23-035865.md","text":"https://secwatch.observer/filing/0001193125-23-035865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/0001193125-23-035865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/d446963d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:40:04.197530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f04fcaf34e32e6efa99ef57662c18e137aec084e","claim":"Cytek Biosciences, Inc. entered into Asset Purchase Agreement with Luminex Corporation valued at approximately $46.5 million in cash (effective 2023-02-13).","evidence_excerpt":"On February 13, 2023, Cytek Biosciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company agreed to acquire certain assets relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services of Luminex (the “Business”) for a purchase price of approximately $46.5 million in cash.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/0001193125-23-035865-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Luminex Corporation"},{"label":"Value","value":"approximately $46.5 million in cash"},{"label":"Effective","value":"2023-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}